Key result
Early termination of anticoagulation at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion led to device-related thrombosis and a fatal stroke.
Case Report (n=1)
Early termination of anticoagulation at 45 days after concomitant AF ablation and LAA occlusion can result in device-related thrombosis and fatal stroke, suggesting a need for prolonged anticoagulation in combined procedures.
Answers are grounded in this paper and cite their sources.
Suggests caution with early anticoagulation stop after combined AF ablation and LAAO; leaves optimal duration open for prospective study.
Catheter ablation therapy for atrial fibrillation (AF) is a safe and effective treatment for patients with both paroxysmal and persistent symptomatic AF. However, given the uncertainty about recurrence after the ablation procedure and continued risk of thromboembolism, it is still recommended to treat with anticoagulation for the long-term prevention of stroke. Left atrial appendage (LAA) occlusion with the WATCHMAN device (Boston Scientific Corp., Natick, MA) has demonstrated equivalent reduction in stroke compared to warfarin as well as a mortality benefit in patients with AF and CHADS2VASC2 score >1,1,2 and it is increasingly being used as an alternative to warfarin for long-term prevention of stroke.
No takes yet. Share an insight, caveat, or question.
Carlson et al. (2017) conducted a case report in Recurrent, symptomatic, drug-refractory atrial fibrillation (n=1). Early termination of anticoagulation (at 45 days) after concomitant AF catheter ablation and WATCHMAN LAA occlusion was evaluated on Device-related thrombosis and stroke. Early termination of anticoagulation at 45 days after concomitant atrial fibrillation catheter ablation and left atrial appendage occlusion led to device-related thrombosis and a fatal stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: